IPM Medical Group Inc., Walnut Creek, California.
Millennium Pain Center, Bloomington, Illinois.
Neurosurgery. 2020 Aug 1;87(2):176-185. doi: 10.1093/neuros/nyz495.
Intractable neck and upper limb pain has historically been challenging to treat with conventional spinal cord stimulation (SCS) being limited by obtaining effective paresthesia coverage.
To assess the safety and effectiveness of the 10-kHz SCS system, a paresthesia-independent therapy, in the treatment of neck and upper limb pain.
Subjects with chronic, intractable neck and/or upper limb pain of ≥5 cm (on a 0-10 cm visual analog scale [VAS]) were enrolled in 6 US centers following an investigational device exemption from the Food and Drug Administration (FDA) and institutional review board approval. Each subject was implanted with 2 epidural leads spanning C2-C6 vertebral bodies. Subjects with successful trial stimulation were implanted with a Senza® system (Nevro Corp) and included in the evaluation of the primary safety and effectiveness endpoints.
In the per protocol population, the primary endpoint (≥50% pain relief at 3 mo) was achieved in 86.7% (n = 39/45) subjects. Compared to baseline, subjects reported a significant reduction (P < .001) in their mean (± standard error of the mean) VAS scores at 12-mo assessment for neck pain (7.6 ± 0.2 cm, n = 42 vs 1.5 ± 0.3 cm, n = 37) and upper limb pain (7.1 ± 0.3 cm, n = 24 vs 1.0 ± 0.2 cm, n = 20). At 12-mo assessment, 89.2% of subjects with neck pain and 95.0% with upper limb pain had ≥50% pain relief from baseline, 95.0% reported to be "satisfied/very satisfied" and 30.0% either eliminated or reduced their opioid intake.
In conclusion, 10-kHz SCS can treat intractable neck and upper limb pain with stable long-term outcomes.
传统的脊髓刺激(SCS)因获得有效的感觉异常覆盖而受到限制,因此难以治疗顽固性颈部和上肢疼痛。
评估 10kHz SCS 系统(一种非感觉异常依赖的治疗方法)治疗颈部和上肢疼痛的安全性和有效性。
在食品和药物管理局(FDA)和机构审查委员会批准的研究设备豁免后,6 家美国中心招募了慢性、难治性颈部和/或上肢疼痛≥5cm(0-10cm 视觉模拟量表[VAS])的受试者。每位受试者都植入了 2 个跨越 C2-C6 椎体的硬膜外导联。成功进行试验刺激的受试者植入了 Senza®系统(NevroCorp),并纳入了主要安全性和有效性终点的评估。
在符合方案人群中,主要终点(3 个月时疼痛缓解≥50%)在 86.7%(n=39/45)的受试者中达到。与基线相比,受试者在 12 个月评估时报告颈部疼痛(n=42,平均[±标准误差均值]VAS 评分 7.6±0.2cm,n=37)和上肢疼痛(n=24,平均[±标准误差均值]VAS 评分 7.1±0.3cm,n=20)的平均 VAS 评分显著降低(P<0.001)。在 12 个月评估时,89.2%的颈部疼痛患者和 95.0%的上肢疼痛患者与基线相比疼痛缓解≥50%,95.0%的患者报告“满意/非常满意”,30.0%的患者要么消除要么减少了阿片类药物的摄入。
总之,10kHz SCS 可以治疗难治性颈部和上肢疼痛,具有稳定的长期疗效。